


North East and North Cumbria Provider Collaborative

# North East North Cumbria Aseptic Manufacturing Production Hub (NENC AMPH)

#MadeInSeaton





# NENC AMPH – Meet the Team



North East and North Cumbria Provider Collaborative









**Kyle Winn** Head of Production

**Dr Laura Davies** Head of QA QC

Adam Walker Interim Head of QA QC

**Craig Muller** Project Manager Helen Delahaye Consultant Project Director

# NENC AMPH – Limited Liability Partnership

# Limited Liability Partnership (LLP) owned by 8 Foundation Trusts.

- Northumbria Healthcare
- Newcastle Hospitals
- Gateshead Health
- Count Durham and Darlington
- North Tees and Hartlepool
- South Tees Hospitals
- South Tyneside and Sunderland
- North Cumbria Integrated Care



# NENC AMPH – Project overview




North East and North Cumbria Provider Collaborative

- Output of > **1,300,000** units per annum
  - Ready To Administer (RtA)
  - Systemic Anti-Cancer Treatments (SACT)
  - Over-labelled products
- Site Location
- 3 4 cleanroom suites
- VHP Isolator Technology
- Automation / Semi Automation
- QC Lab (Micro + Chemistry)
- MS Licenced + WDA








# NENC AMPH – Timeline



NHS



# NENC AMPH – Ready To Administer (RtAs)



North East and North Cumbria Provider Collaborative

- What are RtAs?
  - Antibiotics such as Piperacillin Tazobactam
  - OPATs such as Flucloxacillin
- What are the benefits of RtAs
  - Improved patients care
  - Increased nursing capacity
  - Improving patient experience
  - Increased patient safety
  - Increased productivity via standardisation
- Challenges of implementing RtAs
  - Trust / Finance buy in
  - Economic modelling challenges

If your family or friends were in hospital, would you preferer a nurse to have more time for their bedside care or for them to prepare medicines in a treatment room?






North East and North Cumbria Provider Collaborative



### WYAAT Pharmacy Aseptic Collaboration



₩ wyaat.wyhpartnership.co.uk

@WYAAT\_Hospitals

**Association of Acute Trusts** 



### **Programme Overview |** Transformation of Aseptics Services

### Aim

To design and implement a regional pharmacy aseptic manufacturing capability across the six WYAAT trusts concerning ready-to-administer injectable medicines

### **Objectives and Benefits**

- Increased capacity: satisfy current and future demand of ready to administer aseptic infusions
- Release nursing time to care: currently estimated at 78 WTE across WYAAT
- Cost avoidance: increased efficiency through leveraging economies of scale
- Enhance resilience: Increased capacity for manufacture of RTAs
- Patient safety: reduce prescribing risk, administration errors, missed doses and infection risk
- Product and dose standardisation: reduce risk of errors and increase efficiency
- Utilise novel workforce: maximise career pathways and reduce reliance on traditional pharmacy workforce to prevent destabilisation
- Align with other West Yorkshire & Harrogate workstream e.g. WY&H Cancer Alliance Non-surgical Oncology project

℞ wyaat.wyhpartnership.co.uk



West Yorkshire Association of Acute Trusts



### WYAAT Pharmacy Aseptic Collaboration | Governance Structure



### **Implementation Project Board**

Delivery of the new aseptic hub and transfer of existing services

### Workforce

Develop and implement workforce plan for new hub facility

### **Governance & Finance**

Develop and implement contract between hub and the 6 organisations, outlining governance structure, accountability and finance mechanism.

### **Benefits Realisation / Releasing Nursing Time to Care**

Ensure all organisations are realising benefits as set out in the business case



℞ wyaat.wyhpartnership.co.uk



### **Hub Operational Plan**

### Facility

- 6,500m<sup>2</sup> leased site
- Clean Room Suite with 4 manufacturing rooms capable of producing over 700,000 products per year
- QA/QC department with Microbiology and Chemistry service
- Flexibility between product types
- Co-located with Leeds Pharmacy Store (WDA) and existing overlabelling/repacking service (MS)

### Equipment

- Dual system gassing isolators (VHP)
- Semi-automated processing
- Scope for future fully automated systems

☑ WYAATProgramme@nhs.net

🔇 0113 2065684

℞ wyaat.wyhpartnership.co.uk



West Yorkshire Association of Acute Trusts





# Project Timeline | High Level Overview

		2(	)22				2023				:	2024				2	025	
	Qtr 1	Qtr 2	Qtr 3	Qtr 4	Qtr 1	Qtr 2	2 Qtr	3 Q1	tr 4	Qtr 1	Qtr 2	С	Qtr 3	Qtr 4	Qtr 1	Qtr 2	Qtr 3	Qtr
	JFM	A M J	JAS	SOND	JFN	ЛАМ	JJA	SOI	ND.	JFN	1 A M	l l	ASO	ND	JFM	IAMJ	JA	SON
BUSINESS CASE																		
Outline Business Case																		
Phase 1 Proof of Concept																		
Short Form Business Case																		
NHSE Approval																		
HUB IMPLEMENTATION																		
Lease Agreement																		
Building Design & Fit out																		
Building Fit out (inc. Clean Room)																		
Equipment Procurement & Delivery																		
Validation																		
MHRA Inspection																		
Go Live																		
GOVERNANCE & FINANCE							_											
SLA Contract																		
WORKFORCE				_														
Recruitment Blueprint/Design						_												
Recruitment Planning																		
Early Recruitment (Key Roles)																		
Recruitment (Key Roles)																		
Recruitment (Phase 1)																		
Recruitment (Phases 2-5)																		
₩ WYAATProgramme@nhs	.net	C	011	3 2065	684													
🔉 wyaat.wyhpartnership.co	o.uk	5	@W	YAAT_	Hospi	itals												



## Thank You | UHS & HIOW



₩ WYAATProgramme@nhs.net

℞ wyaat.wyhpartnership.co.uk



0113 2065684




# UHS Adanac Park Development

- 6,599m<sup>2</sup> building
- 3 floors comprised of
  - Sterile services
  - Aseptic Suite
  - Offices
- Initial development aimed to replace on-site aging aseptic production facility
- National aseptic capital allocated to support fitout of aseptic floor providing significant capacity uplift



# Adanac Park – On location




- Adanac Park site (red) will provide base for new aseptic facilities.
- Excellent transport links and infrastructure




# Aseptic Unit Layout

- Design team comprised of UHS, developers and specialist consultants has reached RIBA stage 4/5.
- Primary (awarded) aseptic contractor Enbloc.
- Ex MHRA inspector input has been incorporated into the design and specification decision.
- Unit includes
  - Dedicated gene therapy/AT(I)MP clean room
  - Flexible capacity with oncology and CIVAS areas
  - TPN suite with semi-automated compounding capacity
  - Multiple air-handling units and interchangeable rooms to ensure business continuity



# Local Geographical Coverage

- Well positioned to support HIOW(32) and several surrounding systems
- Confirmed link with Dorset (40) system aseptic lead
- Opportunity to further support other neighbouring systems (30, 31, 35, 36 red boxes)



# Workforce Modelling

- Primary staffing source is current trained workforce
- Phased workforce plan expected to minimise impact on surrounding spoke & commercial aseptic units
- Training plan fully utilising apprenticeships - Pharmacy Technicians & new Science Manufacturing Technicians

	Role	AFC Grade	Existing	23/24	24/25	25/26	26/27	27/28	28/29
Consolidated Staffing Plan (WTE)	Pharmacist	8A	1.00	4.00	4.00	4.00	4.00	4.00	4.80
	PT/SMT	8A	1.00	1.00	1.00	1.00	1.00	1.00	1.00
	Operational Leads	7	1.00	4.00	4.00	4.00	4.00	4.00	4.40
	Pharmacy Assistant	3	6.00	11.00	14.00	14.00	14.00	14.00	17.20
	Pharmacy Assistant	2	11.00	18.00	19.00	19.00	19.00	19.00	26.20
	PT/SMT	7	1.00	1.00	2.00	2.00	2.00	2.00	2.80
	PT/SMT	6	3.00	3.00	3.00	3.00	3.00	3.00	3.00
Cor	PT/SMT	5	12.00	13.00	15.00	15.00	15.00	15.00	19.40
	Adv Senior Support Worker	4	7.00	8.00	9.00	9.00	9.00	9.00	10.20
	Total WTE		46.00	63.00	71.00	71.00	71.00	71.00	89.00

# **Change Management**

- Quality by design early preparation of validation master plan and contamination control strategy
- Moving to licensed service
  - Annex 1 gap analysis
  - Ex MHRA Consultant advice
  - Review of workforce and local practice
- Preparation of process validation
  - Staff training mock isolator
  - Early purchase of key compounding equipment
  - Gas cycle development and process considerations
- Increase in capacity vs existing plans
  - Semi-automation
  - Increasing capacity through the use of rapid transfer
- Additional considerations of moving workforce
  - Beginning to build foundations of staff rotation and cross department training
  - Staff consultation and ongoing project involvement

# **High Level Timelines**



### Phase 1 Workforce Plan

- Development of training programme for conversion to licensed unit
- Recruit additional (QA) posts

### Phase 2 Workforce Plan

- Training of existing staff
- Recruitment of first wave of new assistants
- Establish relationship with higher education supplier

### Phase 3 Workforce Plan

- On-site recruitment with phasing and training across licensed and spoke sites
- Training for bespoke areas of manufacture (gene therapies)

### **HIOW & Other ICS Production Planning**

### Product portfolio & capacity planning

**Dose Standardisation** 



# Greater Manchester Aseptics Hub project

Plan to develop new licensed hub for aseptic production in GM in an off-site hub in addition to an existing licensed production services unit that will act to increase production of aseptic products for GM trusts (Stockport Hub)

Project being hosted by Stockport NHS FT on behalf of GM Acute Trusts (MH trusts not in scope)

Off site hub model in new location found to be the best VfM option for £12m capital funding from NHSE


Invest in semi-automation to increase volumes of aseptic products prepared

Clean room engineers and isolator manufacturer engagement – minimum requirements

- 2 Clean rooms
- 3 Gassing Isolators

# Evolution of Case from 2019 - 2023





- GM Aseptics established group
  within GM pharmacy programme
- Secondment created by GM Chief Pharmacists at risk
- Options Appraisal June 2019
- 'Meeting the unmet need'
- Top 5 Antibiotics in new stand alone unit
- Full automation key to case
- GM Chief Nurses supportive 'in principle'
- Call for Evidence October 2019
- Transformative agenda working collaboratively



# GM Pharmacy Project Management Team – Key learnings



- 1. Rapidly developed a short form business case using core GM pharmacy project management team to outline plans and how GM would utilise capital funds to develop hub
- 2. Would not have been possible to meet tight deadlines without previous work from 'at risk' secondment and options appraisal from 2019 and recent PMO support
- 3. Resourcing requirements adaptations through next phase of project increase in technical input and moderation in PMO support for next phase

# Wider transformation and standardisation

Spoke / Outsourced unit considerations

Training – whilst not directly part of hub project will still carry on at NW level



**Clinical Standardisation** will allow movement of products from spokes to hub releasing capacity

↑ local unit outputs
 ↑ clinical trials
 ↑ new short expiry products

Technical standardisation Standardise policies and Procedures pan GM e.g. Gowning policies to start

Clinical Standardisation e.g. product catalogue biosimilars dosing / diluents / stability





- Excellent engagement from medics, nursing, microbiology, OPAT colleagues, critical care networks, aseptics managers
- Initial Product Catalogue for Day 1 of hub includes antimicrobials, monoclonal antibodies, chemotherapy agents
- Next step to map product volumes onto workforce plan and capacity tools

Project next steps

- Conclude pilot / proof of concept focussed at trusts currently in progress
- Initial URB complete and property search beginning for hub
- Further develop and conclude revenue business case for staffing required to run hub











### Kandarp Thakkar

### Chief Pharmacist & Clinical Director of Medicines Optimisation

# Setting the scene

Largest Trust in the SW – over 1000 beds; nearly every specialty!

**University Hospitals** 

Plymouth NHS Trust

- Current unit over 25 years old; not fit for purpose RED (25 risk) on the Risk Register
- Planning for a new unit been happening over 3 years how do you change appetite to leveraging risk into something tangible?
- OBC approval around preferred option Feb 2023
- FBC finessing benefits, reviewing costs and agreeing funding model – submission expected Nov 2023
- Concurrent system alignment/work TWO hubs
- Design- RIBA stage 3 completed; full bricks and mortar build
- Isolator and EMS procurement nearly complete
- 'Spade in ground' Jan/Feb 2024

# FBC - challenges





# **Maximising benefits**

Modelling

CIVAS

R&D income

Spare capacity

Strategic alignment

# **Reducing the costs**

Phasing of FBC Staffing models



# **Funding streams**

National

What else can you do in the absence of CDEL capital – partnerships, managed service etc.

# Invest in the team!

'Internal' aseptics team – thinking about wider capacity issues Programme / Project Management CC Tech - Project/Validation Consultants 鸓 Architects **e**-e B Braun - External Consultant (Trust 'side') **Ex-MHRA** inspectors



Expertise areas - Mechanical & Electrical, IT, HR etc.

# Automation

- Needs
  - Ability to fit into isolators
  - ISO27001
    accreditation
  - VHP compatible
  - Ease of operator use
  - Ease of set up
  - UK Service Support
  - Data integrity
  - Defined user profiles and secure access
  - Sterile consumables

- Wants
  - WiFi / Network compatible
  - Bar code verifications (diluent, drug, container)
  - HL7 Compatible
  - Speed of filling
  - Versatile filling
    - Syringes
    - I.V. bags (inc. volume withdrawals)
    - Infusors
  - Ability to fill from vials and bulk diluent containers (simultaneously)
  - Minimal aseptic connections
  - Patient specific and batch